CD5 x TGFBR2 bispecific

CD5 x TGFBR2 bispecific is a **preclinical bispecific monoclonal antibody** from Xencor designed to bind **CD5-positive T cells** and **transforming growth factor beta receptor 2** simultaneously, using the company's **XmAb bispecific antibody platform**. Its intended mechanism is to **selectively block TGF-beta signaling on T cells** rather than broadly across tissues, thereby enhancing T-cell activation and promoting antitumor immunity in **solid tumors**. Preclinical data described for this program indicate selective T-cell targeting, broader T-cell coverage than PD-1-directed approaches, and antitumor activity in models including **triple-negative breast cancer**.

Other names

CD5-targeted TGFBR2 bispecificCD-5-targeted TGFBR2 bispecificCD 5-targeted TGFBR2 bispecificCD5 x TGFβR2 bispecific